Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Meclocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 14/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.77 |
| ▸ | MEN1 | O00255 | 9/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.77 |
| ▸ | USP2 | O75604 | 8/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.77 |
| ▸ | RECQL | P46063 | 7/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.77 |
| ▸ | HPGD | P15428 | 7/20 | 0.77 |
| ▸ | THRB | P10828 | 6/20 | 0.77 |
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | LMNA | P02545 | 4/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.77 |
| ▸ | CASP7 | P55210 | 2/20 | 0.77 |
| ▸ | CASP1 | P29466 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meclocycline SCHEMBL5849023 | 1.00 | TDP1 (0.77) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL29365199 | 1.00 | TDP1 (0.77) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL28357495 | 0.89 | TDP1 (0.61) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL24321867 | 0.89 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL21133274 | 0.89 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL21133273 | 0.89 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL3445 | 0.89 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL29427550 | 0.89 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL195707 | 0.89 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL4207351 | 0.88 | TDP1 (0.58) | TDP1KDM4EMEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 808 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| WO-2024089699-A1 | FORMULATIONS FOR USE IN ADDITIVE MANUFACTURING, CONTAINING A TETRACYCLINE COMPOUND AS A LIGHT-ABSORBING SUBSTANCE | COLLPLANT LTD. (IL) | 2024-05-02 | — | — | WO | claimed |
| US-11890421-B2 | Methods for potentiating antimicrobial agents | BEYOND AIR LTD (IL) | 2024-02-06 | — | — | US | claimed |
| US-11852632-B2 | Cancer test device, cancer test method, and staining agent for use in cancer test | MIE UNIVERSITY (JP) | 2023-12-26 | — | — | US | claimed |
| US-20230037210-A1 | CANCER TEST DEVICE, CANCER TEST METHOD, AND STAINING AGENT FOR USE IN CANCER TEST | MIE UNIVERSITY (JP) | 2023-02-02 | — | — | US | claimed |
| US-11555819-B2 | Cancer test device, cancer test method, and staining agent for use in cancer test | MIE UNIVERSITY (JP) | 2023-01-17 | — | — | US | claimed |
| CN-109414151-B | Cancer detection device, cancer detection method, and staining agent for cancer detection | 国立大学法人三重大学 | 2022-11-25 | — | — | CN | claimed |
| CN-114980736-A | Compositions and methods for treating citrus greening disease | 新生命作物科学有限责任公司 | 2022-08-30 | — | — | CN | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| WO-2007147133-A1 | STABILIZED TETRACYCLINE COMPOSITIONS | SERENEX, INC. (US) | 2007-12-21 | — | — | WO | claimed |
| WO-2007099396-A2 | ANTIBIOTIC KIT AND COMPOSITION AND USES THEREOF | FOAMIX LTD. (US) | 2007-09-07 | — | — | WO | claimed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | claimed |
| WO-2007044693-A2 | MULTI-FUNCTIONAL IONIC LIQUID COMPOSITIONS | THE UNIVERSITY OF ALABAMA (US) | 2007-04-19 | — | — | WO | claimed |
| US-20060269485-A1 | Antibiotic kit and composition and uses thereof | FOAMIX LTD. (IL) | 2006-11-30 | — | — | US | claimed |
| CN-1826129-A | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS INC (US) | 2006-08-30 | — | — | CN | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-4650665-A | CALCIUM STEARATE, DEXTRAN, CASTOR OIL | ETHICON, INC. (US) | 1987-03-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | TDP1 1258/4885KDM4E 4586/4885MEN1 3114/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | TDP1 1276/4885KDM4E 4063/4885MEN1 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.